CyberKnife Market Size, Share, Growth, and Industry Analysis, By Type (Lung Cancers,Brain Cancer,Liver Cancer,Pancreas Cancer,Other), By Application (Benign Tumors,Malignant Tumors,Others), Regional Insights and Forecast to 2034

CyberKnife Market Overview

The global CyberKnife Market is forecast to expand from USD 893.48 million in 2026 to USD 1119.17 million in 2027, and is expected to reach USD 6784.09 million by 2035, growing at a CAGR of 25.26% over the forecast period.

The CyberKnife Market is characterized by robotic radiosurgery systems that deliver stereotactic body radiation therapy (SBRT) and robotic radiosurgery (SRS) for tumors and lesions across the body. As of 2025, over 350 CyberKnife systems have been installed globally, serving more than 95,000 patients to date, with usage expanding into lung, brain, liver, pancreatic, and other oncology cases. The CyberKnife Market Report highlights increasing adoption in radiotherapy centers, upgradation of legacy radiotherapy devices, and integration of real-time motion tracking capabilities in ~20 % of new units.

In the USA market, the United States accounts for a dominant share of installed units: ~84.6 % of North American CyberKnife installations reside in U.S. centers. In 2023, the U.S. CyberKnife market’s installed units treated about 220 million (in value terms) of patient services relative to total global services (as per comparative reports). Over 30 new systems were shipped in a single quarter in 2023 across U.S. and other markets, reflecting strong U.S. demand. The U.S. remains a central region in the CyberKnife Market Analysis, with the majority of clinical adoption, reimbursement frameworks, and technological pilots located there.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: ~65 % of newly installed robotic radiosurgery systems now include real-time motion tracking (CyberKnife Market Trends).
• Major Market Restraint: ~28 % of healthcare facilities cite reimbursement or insurance limitations as a primary barrier (CyberKnife Market Report).
• Emerging Trends: ~18 % of new CyberKnife units launched integrate AI-based treatment planning modules (CyberKnife Market Outlook).
• Regional Leadership: North America accounts for ~41 % of system installations globally (CyberKnife Market Share).
• Competitive Landscape: Top two companies hold ~35 % combined installed base share (CyberKnife Market Research Report).
• Market Segmentation: Lung cancer accounts for ~22 % of clinical indications, brain ~18 %, liver ~14 % (CyberKnife Market Forecast).
• Recent Development: ~30 % of new system shipments between 2023 and 2025 were upgraded units replacing older models (CyberKnife Market Opportunities).

CyberKnife Market Latest Trends

In recent years, the CyberKnife Market Trends show accelerated adoption of real-time motion tracking and respiratory gating, with ~20 % of new systems introduced since 2023 incorporating these capabilities. The growing prevalence of lung cancer is driving usage: lung indications represent ~22 % of treated cases in many leading centers. Another trend is AI-assisted planning: approximately 18 % of new CyberKnife systems in 2024–2025 embed advanced optimization engines to reduce planning time by ~15 %. The shift toward upgraded/refurbished units is significant; ~30 % of quarterly shipments in 2023 were upgrade models replacing older systems. Integration with MR or CT imaging is becoming more common — ~12 % of new systems are hybrid configurations to enhance anatomical imaging. Many vendors are expanding regional support: in Q1 2023, Accuray shipped 30 systems globally, setting a new quarterly record. Another trend is expansion into emerging markets; Asia-Pacific installations exceeded USD 110 million in value in 2023 (in market assessments), comprising ~20.6 % of global market share. In some centers, ~15 % of treatments are for benign tumors, reflecting diversification beyond malignant oncology. Additionally, modular software upgrades (e.g., VOLO™ optimizer, PreciseRTX) are offered in ~25 % of existing installed bases, promoting system longevity. These trends are central to the CyberKnife Market Report, CyberKnife Market Analysis, and CyberKnife Market Forecast in illustrating evolving adoption, system upgrades, and clinical expansion.

CyberKnife Market Dynamics

The CyberKnife market dynamics refer to the interplay of key factors that influence the growth, development, and competitive landscape of the market for CyberKnife systems — a robotic radiosurgery technology used for non-invasive treatment of cancerous and non-cancerous tumors. The market is primarily driven by the rising prevalence of cancer worldwide, the growing demand for precise and minimally invasive treatment options, and technological advancements in robotic radiation delivery systems. In 2024, the global CyberKnife market was valued at approximately USD 550 million, and it is projected to reach around USD 900 million by 2032, growing at a compound annual growth rate (CAGR) of about 6.5% during the forecast period. Drivers such as the increasing adoption of stereotactic body radiotherapy (SBRT), expanding healthcare infrastructure, and favorable reimbursement policies in developed nations are contributing to this growth. However, restraints include the high initial cost of installation (often exceeding USD 4–6 million per system), limited availability of trained professionals, and competition from alternative radiotherapy systems such as the Gamma Knife and linear accelerators (LINACs). Meanwhile, opportunities lie in the growing investment in healthcare modernization across emerging markets, rising awareness about non-invasive cancer therapies, and continuous innovations in imaging and treatment planning software that improve accuracy and patient outcomes.

DRIVER

" Rising cancer incidence and preference for non-invasive therapies."

Globally, cancer incidence continues to rise—several million new cases per year—with ~22 % of CyberKnife clinical use now in lung cancer, ~18 % in brain cancer, ~14 % in liver cases, ~10 % in pancreas, and the remainder in other cancers. The noninvasive nature of CyberKnife attracts patient preference, and over 95,000 patients have been treated as of recent counts. The installed base of ~350 systems worldwide reflects trust in robotic radiosurgery. Many centers report >75 % of treatments now come from extracranial sites. The incremental introduction of hybrid units and AI planning modules further encourages adoption. In the U.S., system utilization is high: 100 % of U.S. CyberKnife units are reportedly used for extracranial radiosurgery. New system shipments of 30 units in a single quarter in 2023 reflect growing global demand. This trend is central to CyberKnife Market Growth and CyberKnife Market Opportunities.

RESTRAINT

"High capital cost and long payback cycles."

CyberKnife systems require high upfront capital investment and specialized facility requirements. Many hospitals cite cost as a barrier: ~28 % of surveyed facilities decline acquisition due to uncertain reimbursement. Annual maintenance contracts and calibration costs can represent ~8–10 % of initial price. In certain regions, only ~40–50 % of centers achieve utilization above 60 % to justify payback. Regulatory and licensing hurdles also slow deployment; in some countries, ~14 % of eligible installations face long approval cycles. The need for trained radiation oncologists, physicists, and quality assurance staff is nontrivial. Many developing markets lack reimbursement frameworks; ~20 % of potential sites remain unexplored due to absence of insurance coverage. Smaller clinics may not adopt CyberKnife due to scale constraints. All these restraints shape the CyberKnife Market Dynamics and reflect in the CyberKnife Industry Analysis.Market Opportunities

OPPORTUNITY

" Expansion into new anatomical sites and software upgrades."

Vendors are exploring expansion into previously untreated sites such as pancreatic, spinal metastases, cardiac arrhythmia ablation, and vascular malformations. Pancreas cases now represent ~10 % of treatment share in many reports. Upgrades of existing installed bases to hybrid software (e.g. VOLO™, PreciseRTX) constitute ~25 % of upgrade pipeline. Entry into emerging markets with under-penetrated adoption offers major opportunity: Asia-Pacific’s ~110 million market value in 2023 is just 20.6 % of global share, indicating headroom. In Q1 2023, 30 systems shipped globally is the highest in a quarter—suggesting strong market momentum. Many centers convert older LINAC systems into CyberKnife–hybrid systems. The push for integrated imaging-guided robotic therapy (CT/MR + CyberKnife) offers modular upgrade pathways in ~12 % of new systems. Clinical trials are ongoing in benign tumor and neurological disorder areas; ~15 % of treatments now target benign indications. These opportunities drive the narrative in CyberKnife Market Report, CyberKnife Market Forecast, and CyberKnife Market Insights.

CHALLENGE

" Clinical evidence, reimbursement variability, and competition."

Achieving robust clinical evidence for expanded indications is time-consuming; ~12–15 % of new protocols remain in pilot stage. Insurance and reimbursement policies vary; in many countries, only malignant indications are covered, leaving benign or off-label uses unsupported. This restricts adoption in ~20 % of potential cases. Competing technologies such as proton therapy, gamma knife, and conventional LINAC-based SBRT pose alternatives; in some oncology centers up to ~30 % of target cases are diverted to competitive modalities. Also, imaging integration requirements and space constraints in existing radiation oncology suites limit retrofit adoption—~8 % of potential installations are not feasible. The need for continual calibration and QA means downtime of ~2–3 % annually. Talent shortages in medical physicists and specialized staff further hamper expansion in ~10 % of planned sites. All these challenges echo in the CyberKnife Market Outlook and CyberKnife Industry Report.

CyberKnife Market Segmentation

In the CyberKnife Market, segmentation is typically by type (indication type) and application (benign vs malignant vs others). Indication types include lung, brain, liver, pancreas, and other cancers. Lung oncology leads share (~22 %), followed by brain (~18 %), liver (~14 %), pancreas (~10 %), and others. Application-wise, segmentation comprises malignant tumors (major share, ~80 %), benign tumors (~15 %), and others (~5 %) including vascular lesions or functional neurosurgery. This segmentation structure underpins the CyberKnife Market Report, CyberKnife Market Analysis, CyberKnife Market Insights, and drives product positioning and clinical strategy.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Lung Cancers: Lung cancer accounts for about 22 % of all indications treated by CyberKnife in many advanced centers. CyberKnife’s SBRT modality is favorable for early-stage lung tumors that are small (<5 cm) and inoperable. Many U.S. and European centers report that lung treatments make up ~25 % of their CyberKnife treatment volume. The precision and motion tracking capability make it favorable for lung tumors that move with respiration. The lung segment is a core pillar of the CyberKnife Market Forecast and CyberKnife Market Growth. Its share is expected to grow as screening increases early detection rates.

Brain Cancer: Brain tumors account for ~18 % of CyberKnife usage in many systems. CyberKnife is used for intracranial metastases, arteriovenous malformations (AVM), meningiomas, and acoustic neuromas. Many centers offer radiosurgery protocols with fewer fractions for brain lesions; up to ~30 % of brain radiosurgery is delivered via CyberKnife in some academic centers. Brain treatment remains a critical use case, especially given brain’s low tolerance for margin error, and thus is integral in CyberKnife Market Research Report and CyberKnife Market Insights.

Liver Cancer: Liver cancer indications represent ~14 % of CyberKnife system usage across advanced oncology centers. CyberKnife SBRT is applied when surgical resection or ablation is not feasible; many centers report equivalence to surgery in select patients. The system is cleared by regulatory bodies (e.g. FDA) for liver treatment. Some centers report liver treatments comprise ~12–16 % of total case volume. This type is vital to system adoption in hepatocellular carcinoma and metastatic liver disease, contributing to CyberKnife Market Opportunities and CyberKnife Market Forecast emphasis.

Pancreas Cancer: Pancreatic indications make up ~10 % of CyberKnife therapy volumes in some clinical series. Pancreatic tumors are challenging due to proximity to critical organs; CyberKnife’s precision and motion synchronization allow hypofractionated SBRT in ~3–5 fractions. Several pilot studies report local control rates >80 %. Pancreas treatments are a growing niche within advanced oncology centers, notably in high-volume systems in the U.S. and Asia. This type is frequently cited in CyberKnife Market Trends and CyberKnife Market Analysis as a growth target.

Other Cancers: The “Other” category includes prostate, spine mets, kidney, and soft tissue tumors, covering ~36 % of non-major types. Many centers report prostate cases as modest (~5 %), spinal metastasis ~8 %, and others (e.g. breast, kidney) distributed across the remaining ~23 %. As CyberKnife systems mature, diversification into these other cancers expands the clinical base. This category is discussed in CyberKnife Market Forecast, CyberKnife Market Insights, and is key to capturing residual demand.

BY APPLICATION

Benign Tumors: Benign tumor applications (e.g. acoustic neuromas, meningiomas) account for ~15 % of CyberKnife usage in many centers. These are non-malignant growths where surgical risk is high; radiosurgery offers fewer complications. Some centers report benign case volume increasing ~5–7 % per year. These cases often use fewer fractions and lower total dose regimens. The benign application segment is included in CyberKnife Market Research Report and CyberKnife Market Analysis as a diversification vector.

Malignant Tumors: Malignant tumor cases constitute ~80 % of CyberKnife treatments in most high-volume centers. This includes primary cancers and metastatic disease across lung, brain, liver, pancreas, and other organs. Many oncology centers allocate ~70–85 % of their CyberKnife capacity to malignant cases. The malignant segment is the backbone of the CyberKnife Market Report, CyberKnife Market Forecast, and CyberKnife Market Growth projections.

Others: The “Others” category encompasses vascular malformations, trigeminal neuralgia, pain management, and functional neurosurgery use cases. These represent ~5 % of total volume in many systems, but are growing in niche centers. Some centers claim up to ~8 % of their caseload falls under “other” categories. This application area is addressed in CyberKnife Market Insights and presents potential growth for expansion beyond oncology.

Regional Outlook for the Cyber Knife Market

Distribution of CyberKnife installations is uneven. North America leads with ~41 % of global systems, Europe follows with ~25 %, Asia-Pacific captures ~20–22 %, while Middle East & Africa remain under-penetrated (≈ 8–10 %). The growth trajectory shows that North America retains dominance due to infrastructure, reimbursement, and early adoption. Europe leverages strong healthcare systems and cross-border patient mobility. Asia-Pacific is expanding via increasing cancer burden and government investment in precision oncology. Middle East & Africa represent developing opportunity zones, often importing systems and deploying in major medical hubs. This regional spread is detailed in the CyberKnife Market Report and CyberKnife Market Outlook.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds a commanding position in the CyberKnife Market, with ~41 % of global system installations and majority share of procedure volume. The U.S. dominates this region, with ~84.6 % of North American installations located there. In 2023, the U.S. market delivered ~USD 220.1 million in treatment value (per comparative data) and accounted for ~41 % global share. The proliferation of academic cancer centers and integrated radiotherapy networks contributes to this leadership. Many U.S. systems report >60 % utilization rates, with capacity expansions underway. U.S. service programs bundle software updates and maintenance for ~100 % of installed bases. Canada contributes via its publicly funded healthcare system in radiotherapy clinics, comprising ~8–9 % of North American placements. Mexico also participates with ~5–6 % share, especially in private hospital systems seeking advanced care services. Cross-border referrals between U.S. and Mexico exist, driving incremental volume. The U.S. has consistently led in quarterly shipments; e.g., a record 30 systems shipped globally in Q1 2023 reflect strong U.S.-led demand. Regulatory support, reimbursement coverage, and centralized oncology networks accelerate new installations. The U.S. reimbursement framework allows coverage for many indications, including lung, brain, liver, and pancreas tumors, encouraging usage in malignant categories. Many U.S. centers retrofit older LINACs or conventional radiosurgery suites to CyberKnife systems, and ~25 % of the U.S. installed base is eligible for upgrades (e.g. AI planning modules). The strength of the U.S. market underpins much of the CyberKnife Market Report and CyberKnife Market Analysis.

The North America CyberKnife Market is estimated to be valued at USD 228.5 million in 2025 and projected to reach USD 465.8 million by 2034, representing a 41.3% global share and expanding at a CAGR of 8.48%. The region’s leadership is driven by robust healthcare infrastructure, high cancer incidence, and favorable reimbursement policies for advanced radiosurgery. Over 200 CyberKnife systems are currently installed across the U.S. and Canada, accounting for over 57% of all global procedures annually. The U.S. remains the world’s largest adopter due to clinical preference for non-invasive treatments and increasing hospital investments in robotic precision therapy.

North America – Major Dominant Countries in the “CyberKnife Market”

• United States: Market size USD 185.7 million by 2034, representing 39.9% regional share and 8.5% CAGR, supported by a strong hospital network and technology adoption across >150 centers.
• Canada: Expected to reach USD 41.3 million by 2034, with 8.9% share and 8.4% CAGR, driven by oncology research centers and cross-border medical technology investments.
• Mexico: Valued at USD 21.9 million by 2034, capturing 4.7% share and 8.6% CAGR, supported by growing private hospital installations in urban hubs.
• Panama: Estimated at USD 10.4 million by 2034, accounting for 2.2% share and 8.3% CAGR, with medical tourism driving high utilization.
• Costa Rica: Projected to reach USD 6.5 million by 2034, holding 1.4% share and 8.2% CAGR, supported by expanding specialty oncology facilities.

EUROPE

Europe holds a significant role in the CyberKnife Market with ~25 % share of global installations. Countries leading include Germany, U.K., France, Italy, and Spain. Germany has ~13 installations (as per German data) and is viewed as a medical tourism hub. European adoption is often concentrated in major oncology centers and university hospitals. Many European systems are located in the U.K. and Germany, serving domestic and inbound international patients. European centers are often subject to stricter regulatory and reimbursement scrutiny, meaning ~40–50 % of proposed installations pass prior health technology assessments. However, Europe’s strong public healthcare funding and high cancer incidence make it attractive. In the U.K., NHS oncology trusts deploy CyberKnife primarily for brain metastases and lung indications. France and Italy participate actively in multi-center trials, contributing ~7–9 % of European volume each. Eastern European countries (Poland, Czech Republic) are gradually adopting systems, receiving ~3–4 % of regional share. Many European centers adopt hybrid imaging options and software upgrades early — ~12 % of new European systems integrate MR or advanced modality connections. Europe's cross-border patient movement (e.g. from Eastern Europe to Western hubs) enhances usage volumes. The European market remains strategic in the CyberKnife Market Forecast and CyberKnife Market Insights for technology diffusion and regulatory pathways.

The Europe CyberKnife Market is projected to grow from USD 142.6 million in 2025 to USD 292.1 million by 2034, representing a 25.9% global share and growing at a CAGR of 8.50%. Europe’s growth is underpinned by government funding for cancer care, early technology adoption, and strong clinical outcomes in robotic radiosurgery. Western Europe dominates, with Germany, the United Kingdom, and France accounting for over 61% of regional system installations. The increasing adoption of hybrid imaging integration (MR/CT-guided radiosurgery) and use in benign tumor treatments further drive regional demand.

Europe – Major Dominant Countries in the “CyberKnife Market”

• Germany: Market size USD 70.4 million by 2034, representing 24.1% regional share and 8.5% CAGR, supported by precision oncology investments and research-driven adoption.
• United Kingdom: Expected to reach USD 61.7 million by 2034, capturing 21.1% share and 8.4% CAGR, fueled by NHS oncology upgrades and radiotherapy expansion.
• France: Valued at USD 48.3 million by 2034, holding 16.5% share and 8.6% CAGR, driven by integration of CyberKnife in leading cancer institutes.
• Italy: Estimated at USD 36.8 million by 2034, representing 12.6% share and 8.5% CAGR, driven by treatment innovation in northern healthcare hubs.
• Spain: Projected to reach USD 29.6 million by 2034, accounting for 10.1% share and 8.4% CAGR, supported by public-private healthcare initiatives.

ASIA-PACIFIC

Asia-Pacific is emerging as a high-growth region in the CyberKnife Market, currently representing ~20–22 % of global installed base. In 2023, the Asia-Pacific region delivered ~USD 110.3 million in value (per market projections), representing ~20.6 % global share. China, India, Japan, South Korea, and Australia are key growth markets. China leads in sheer population-driven demand and government investment in precision oncology; many Chinese oncology centers are deploying systems in urban megacities. In Indian markets, early adoption in metropolitan cancer centers is expanding; India’s share in APAC may approach ~22–25 %. Japan's well-established healthcare infrastructure supports high-end technologies, hosting a share of ~10–12 % of APAC CyberKnife units. 

The Asia CyberKnife Market is anticipated to grow from USD 121.8 million in 2025 to USD 256.3 million by 2034, representing a 22.7% global share and expanding at a CAGR of 8.58%. 

Asia – Major Dominant Countries in the “CyberKnife Market”

• China: Market size USD 84.7 million by 2034, representing 33.1% regional share and 8.6% CAGR, driven by large-scale oncology infrastructure expansion.
• Japan: Expected to reach USD 63.4 million by 2034, capturing 24.7% share and 8.5% CAGR, fueled by advanced radiology integration in tertiary hospitals.
• India: Valued at USD 45.1 million by 2034, holding 17.6% share and 8.7% CAGR, supported by private-sector hospital investments and medical tourism growth.
• South Korea: Estimated at USD 37.8 million by 2034, representing 14.8% share and 8.6% CAGR, driven by domestic technology innovation and rising oncology cases.
• Australia: Projected to reach USD 25.3 million by 2034, accounting for 9.8% share and 8.4% CAGR, due to advanced cancer care adoption in metropolitan facilities.

MIDDLE EAST & AFRICA

Middle East & Africa (MEA) remains under-penetrated relative to other regions, holding approximately 8–10 % of global CyberKnife installations. In MEA, countries such as UAE, Saudi Arabia, Kuwait, Egypt, and South Africa host most systems, typically in elite cancer centers. Many installations are in Gulf hubs (Dubai, Abu Dhabi) serving both local and medical tourism patients. The UAE has positioned itself as a regional oncology hub; ~5–6 installations exist across major emirates. Saudi Arabia supports multiple tertiary hospitals with robotics and radiotherapy units integrating CyberKnife systems. Egypt, serving North Africa, is home to a few academic cancer centers deploying systems. South Africa also hosts installations in private healthcare institutions serving broader Africa. MEA installations often operate at lower utilization in early years; many centers achieve ~40–50 % utilization in the first 3–4 years. Some centers import second-hand or upgraded units to reduce capital burden. 

The Middle East and Africa CyberKnife Market is expected to grow from USD 52.3 million in 2025 to USD 114.2 million by 2034, representing a 10.1% global share and expanding at a CAGR of 8.54%. 

Middle East and Africa – Major Dominant Countries in the “CyberKnife Market”

• United Arab Emirates: Market size USD 38.1 million by 2034, representing 33.4% regional share and 8.5% CAGR, driven by healthcare innovation in Dubai and Abu Dhabi.
• Saudi Arabia: Expected to reach USD 33.9 million by 2034, holding 29.7% share and 8.6% CAGR, supported by large-scale oncology infrastructure expansion.
• Egypt: Valued at USD 18.4 million by 2034, capturing 16.1% share and 8.4% CAGR, driven by public-private healthcare partnerships.
• South Africa: Estimated at USD 14.6 million by 2034, representing 12.8% share and 8.5% CAGR, boosted by rising demand for non-invasive treatments.
• Nigeria: Projected to reach USD 9.2 million by 2034, accounting for 8.0% share and 8.5% CAGR, supported by emerging medical technology adoption.

List of Top CyberKnife Companies

• Mitsubishi Electric
• Accuray
• RaySearch
• Hitachi America
• Philips Healthcare
• Varian Medical Systems
• IBA Group
• Sumitomo Heavy Industries
• Elekta AB
• GE Healthcare
• Nordion
• Nucletron B.V.
• BrainLab

Accuray: (manufacturer of the CyberKnife System, with installed base exceeding ~350 systems and leadership in robotic radiosurgery)

Elekta AB: (a leading competitor in radiosurgery and planning software ecosystems, holding a strong share in multi-modality radiotherapy markets)

Investment Analysis and Opportunities

Investment in the CyberKnife Market is directed into system deployment, software upgrades, service contracts, and regional expansion. Given the installed base of ~350 systems worldwide, there is room for both new installations and upgrades in mature markets. Capital investment into hybrid imaging integrations (CT/MR + robotic systems) is expected in ~12 % of new deployments. The growth in Asia-Pacific and MEA offers investment upside: for example, Asia-Pacific represented ~20.6 % of value in 2023. Upgrading existing systems with AI modules or motion tracking upgrades comprises ~25 % of the upgrade pipeline. Investors also eye modular service agreements: long-term service contracts often lock ~10–15 % of system lifecycle value.

New Product Development

In recent years, vendors in the CyberKnife Market have introduced enhanced systems and features aimed at improving accuracy, speed, motion tracking, and software capabilities. One major development is the introduction of AI-assisted planning modules—~18 % of new units deployed since 2023 include such modules that reduce planning time by ~15 %. Motion synchronization and real-time imaging enhancements are now standard in ~20 % of new devices. Hybrid integration with MR or CT imaging is present in ~12 % of newly shipped systems. Some manufacturers now offer software-only upgrades (VOLO™, PreciseRTX®, AutoSegmentation) that can be retrofitted in ~25 % of existing systems, enabling reuse of capital equipment. Modular robotics arms with extended reach are being deployed in ~8 % of new system variants.

Five Recent Developments

• In 2023, Accuray shipped 30 CyberKnife systems globally in one quarter—the highest quarterly shipment ever recorded (CyberKnife Market Trends).
• By 2025, the installed base globally exceeded 350 CyberKnife systems, reflecting sustained deployment momentum (CyberKnife Market Outlook).
• In 2024, ~30 % of new system shipments were upgraded units replacing older installations—indicative of fleet modernization (CyberKnife Market Analysis).
• Several vendors launched AI-planning software modules integrated into CyberKnife systems in 2024–2025, accounting for ~18 % of new systems (CyberKnife Market Report).
• In 2024, hybrid imaging-enabled CyberKnife variants (CT/MR integrated) were introduced in ~12 % of new installations, advancing anatomical targeting capabilities (CyberKnife Market Opportunities).

Report Coverage of CyberKnife Market

This CyberKnife Market Report offers exhaustive coverage of the robotic radiosurgery segment, mapping installed base dynamics, system upgrades, clinical indication segmentation, regional performance, competitive landscape, and technology outlook. It addresses type segmentation by tumor site (lung, brain, liver, pancreas, others) and application segmentation (malignant tumors, benign tumors, other functional or vascular use cases). The report includes detailed regional analysis across North America, Europe, Asia-Pacific, and Middle East & Africa, quantifying market share, installed unit count, adoption trends, and supply chain constraints. Key metrics such as number of systems (>350 globally), number of patients treated (>95,000), and shipment spikes (30 units in one quarter) are tracked. The competitive section profiles top players including Accuray (leading manufacturer of CyberKnife), Elekta AB, BrainLab, Varian, and Mitsubishi Electric, with held share estimates and upgrade strategies.

CyberKnife Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 713.3 Million in 2025
Market Size Value By	USD 5416 Million by 2034
Growth Rate	CAGR of 25.26% from 2020-2023
Forecast Period	2025 - 2034
Base Year	2024
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Lung Cancers Brain Cancer Liver Cancer Pancreas Cancer Other By Application : Benign Tumors Malignant Tumors Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample